Lilly provides update on 2024 revenue guidance, announces 2025 …
Jan 14, 2025 · For Q4 2024, Lilly now expects worldwide revenue to be approximately $13.5 billion, representing growth of 45% compared to Q4 2023. This includes approximately $3.5 billion for Mounjaro ® and $1.9 billion for Zepbound ®. In addition to the uptake of Mounjaro and Zepbound, Lilly saw strong performance from its oncology, immunology and ...
Quarterly Results | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
News Release - Eli Lilly and Company
Feb 6, 2024 · New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products(ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance.
Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion …
Jan 14, 2025 · Eli Lilly expects fourth-quarter 2024 revenue of approximately $13.5 billion, representing a 45% year-over-year growth compared to the consensus of $13.97 billion. The company’s expected 2024...
JP Morgan 2025: Eli Lilly misses 2024 revenue estimate by $400m
Jan 15, 2025 · The revised outlook, discussed at the JP Morgan Healthcare Conference 2025 on 14 January, has been attributed to stocking levels and unexpected market dynamics in Q4 2024 in the diabetes...
Eli Lilly's Q4 2024 Earnings: What to Expect - Nasdaq
Jan 13, 2025 · Analysts expect Eli Lilly’s EPS to climb 107.9% to $13.14 in fiscal 2024, up from $6.32 in 2023. In fiscal 2025, EPS is projected to increase by 82.9% annually to $24.03.
Eli Lilly (LLY) Q4 2023 Earnings Call Transcript - The Motley Fool
Feb 6, 2024 · Eli Lilly (LLY 2.45%) Q4 2023 Earnings Call Feb 06, 2024, 10:00 a.m. ET. Contents: Prepared Remarks; Questions and Answers; Call Participants; Prepared Remarks: Operator
Weight-Loss Drugs Buoy Eli Lilly's Q4 Earnings and 2024 Outlook
Feb 6, 2024 · Eli Lilly (LLY) reported strong fourth-quarter earnings driven by demand for its weight-loss drugs, and projected sales could rise over 20% this year. Eli Lilly forecast 2024 sales of $40.4...
Eli Lilly Expects Q4 Revenue Below Guidance, Sees 2025 Revenue …
Jan 14, 2025 · Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and ...
Eli Lilly (LLY) Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales
Feb 6, 2024 · LLY - Free Report) reported fourth-quarter 2023 adjusted earnings per share (“EPS”) of $2.49, which beat the Zacks Consensus Estimate of $2.46 per share. Earnings rose 19% year over year....
- Some results have been removed